References
- Ochi T, Iwase R, Yonemasu K, Matsukawa M, Yoneda M, Yukioka M, et al. Natural course of joint destruction and fluctuation of serum C1q levels in patients with rheumatoid arthritis. Arthritis Rheum. 1988;31(1):37–43.
- Ochi T, Yonemasu K, Iwase R, Sasaki T, Tsuyama K, Ono K. Serum C1q levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis. Arthritis Rheum. 1984;27(8):883–7.
- Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66(9):1221–6.
- Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67(2):212–7.
- Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S, et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol. 2009;36(2):266–72.
- Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62.
- Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K, et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol. 2009;28(4):445–51.
- Ochi T, Yonemasu K, Ono K. Immunochemical quantitation of complement components of Clq and C3 in sera and synovial fluids of patients with bone and joint diseases. Ann Rheum Dis. 1980;39(3):235–40.
- Yonemasu K. Anti-human C1q: rapid and simple method for preparing monospecific antisera. J Immunol Methods 1975;9(2):185–94.
- 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 2008;58(2):S15.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
- Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000;59(6):455–61.
- Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J. 1991;274 (Pt 2):481–90.
- Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
- Holers VM, Banda NK. Complement in the initiation and evolution of rheumatoid arthritis. Front Immunol. 2018;9:1057.
- Trouw LA, Daha N, Kurreeman FA, Bohringer S, Goulielmos GN, Westra HJ, et al. Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin Exp Immunol. 2013;173(1):76–83.
- Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002;46(4):934–45.
- Sawada T, Kanzaki T, Hashimoto S, Suzuki A, Yamada R, Odawara M, et al. Citrullinated antigens as C1q-binding and monoclonal rheumatoid factor (mRF)-binding peptides in synovial fluids from rheumatoid arthritis patients. Clin Exp Rheumatol 2009;27(6):989–92.
- Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum. 2006;54(4):1143–50.
- Tenner AJ. C1q receptors: regulating specific functions of phagocytic cells. Immunobiology. 1998;199(2):250–64.